CALL: 516-570-3071 CALL: TOLL FREE 844-800-6657
CONTACT US TODAY
Geoffrey R. Kaiser
visit: superlawyers.com
Geoffrey R. Kaiser vCard | PDF gkaiser@kaiserfirm.com
Prior to star ng Kaiser Law Firm, PLLC, Mr. Kaiser served for nearly ten years with the United States Department of Jus ce in the Criminal Divisions of the United States A orney’s Offices for the Eastern and Southern Districts of New York, two of the premier prosecu ng offices within the Jus ce Department. While at the Jus ce Department, Mr. Kaiser directed a wide array of white collar inves ga ons and prosecu ons, including but not limited to those involving health care fraud, securi es fraud, tax fraud, mortgage fraud, mail and wire fraud, and bank fraud, as well as money laundering and illegal trafficking in counterfeit goods and marks. A number of those inves ga ons involved major global business organiza ons. As Chief of Health Care Fraud Prosecu ons and Deputy Chief of Public Integrity in the Eastern District U.S. Privacy - Terms A
’ Offi
M K i
di
t di
ff
d ll
i
t i di id l
d
A orney’s Office, Mr. Kaiser directed inves ga ons of fraud allega ons against individuals and corpora ons made under the False Claims Act, the An -Kickback Statute, the HIPAA privacy laws, the Food, Drug and Cosme c Act, and the Prescrip on Drug Marke ng Act. Mr. Kaiser also exercised oversight responsibili es within the Public Integrity Sec on and over all health care fraud cases within the Eastern District of New York. Moreover, during his career as a federal prosecutor, Mr. Kaiser directed and advised federal law enforcement agents from numerous agencies, including but not limited to the Federal Bureau of Inves ga on, Food and Drug Administra on, United States Postal Inspec on Service, Department of Health and Human Services, Secret Service, Drug Enforcement Administra on and Bureau of Alcohol, Tobacco, Firearms and Explosives. Mr. Kaiser has received numerous recogni ons and honors for his efforts. Mr. Kaiser also has served as a Managing Director with Navigant Consul ng, an interna onal publicly-held consul ng firm, in two of the firm’s prac ce groups: Disputes and Inves ga ons and Healthcare Disputes, Compliance and Inves ga ons. While at Navigant, Mr. Kaiser focused on business intelligence services, internal inves ga ons, integrity monitorships and brand protec on services. Mr. Kaiser also has deep experience in private sector legal prac ce. As a li ga on a orney at preeminent law firms in Manha an and on Long Island, Mr. Kaiser handled a diverse array of commercial li ga on ma ers involving an assortment of business disputes. Mr. Kaiser has par cular experience and exper se in the prosecu on of claims brought under the False Claims Act. A er gradua ng law school, Mr. Kaiser served for two years as law clerk to The Honorable Fritz W. Alexander II (Late), who sat on New York’s highest court as an Associate Judge of the New York State Court of Appeals. Mr. Kaiser holds a Juris Doctor degree from New York University School of Law, and a Bachelor of Arts degree with Honors from the University of Virginia, where he also graduated Phi Beta Kappa. Mr. Kaiser is an adjunct professor of law at St. John’s University School of Law, where he teaches Health Care Fraud.
REPRESENTATIVE MATTERS Health Care Fraud and The False Claims Act Nego ated False Claims Act se lement on behalf of Relator against large New York regional hospice based on allega ons that the hospice fraudulently billed Medicare and Medicaid for medically unnecessary levels of care and falsely cer fied pa ents as terminally ill, and engaged in a retaliatory discharge of Relator for raising compliance concerns. Nego ated False Claims Act se lement on behalf of Relator against a large municipal hospital based on allega ons that the hospital (1) fraudulently billed Medicare and Medicaid for podiatry hospital services and professional services in viola on of program requirements rela ng to resident supervision and where some services were performed by residents who lacked legal authoriza on to par cipate in a graduate educa on program, and (2) sought reimbursement of gradua on educa on program costs for a podiatry residency program that violated standard and was operated fraudulently
was operated fraudulently Defended mul ple medical providers, individual and corporate, against allega ons and government inves ga ons brought under the False Claims Act. Inves gated Nichols Ins tute Diagnos cs and its parent, laboratory giant Quest Diagnos cs, under the False Claims Act and the Food, Drug and Cosme c Act, based on allega ons of quality issues affec ng various blood tests, including those used to measured parathyroid hormone levels in dialysis and other pa ents. Inves ga on led to a $302 million global se lement with the federal government, then one of the largest se lements ever obtained by the Department of Jus ce in a medical device case. Inves gated Orphan Medical, Inc. and its parent Jazz Pharmaceu cals, Inc. under the False Claims Act and the Food, Drug and Cosme c Act, based on allega ons that Orphan Medical marketed the “date rape” drug GHB, under the brand name “Xyrem,” for medical uses not approved by the U.S. Food and Drug Administra on. Nego ated $20 million global se lement with Jazz Pharmaceu cals. Inves gated global pharmaceu cal manufacturers in rela on to fraud allega ons indica ng possible viola ons of federal laws, including the An -Kickback Statute and Prescrip on Drug Marke ng Act. Retained as expert by global device manufacturer to advise regarding impact of An -Kickback statute on certain contractual arrangements with physician consultant. Inves gated and prosecuted mul ple health care corpora ons and medical providers related to allega ons of fraudulent billing prac ces. Financial Fraud Inves ga ons
Inves gated The Bank of New York for its involvement in the dissemina on of fraudulent escrow agreements and failure to report evidence of criminal ac vity involving those agreements as required under the Bank Secrecy Act. Inves ga on culminated in landmark agreement manda ng sweeping reforms of the bank’s suspicious ac vity repor ng and an -money laundering procedures, ongoing reviews of the bank’s opera ons by an independent examiner and payment of $24 million. Inves gated a Long Island-based mortgage bank and its employees for their involvement in a conspiracy to defraud the Department of Housing and Urban Development through fraudulent mortgage applica ons containing falsified employment and income data. Part of prosecu on team that inves gated Symbol Technologies, Inc. for its involvement in a massive accoun ng fraud. Prosecuted Symbol’s former Director of Finance. Prosecuted a orney and mul ple brokers for concealing exorbitant commissions earned on the sale of private placements formed to fund Hollywood film ventures. Publica ons “False Claims Act Materiality Standard’s Odd Applica on to Payment Terms” (Law360, October 2020) “Th F d
lA
Ki kb k St t t
dS f H b
” (C A th
A
i
B
A
i
J l
“The Federal An -Kickback Statute and Safe Harbors” (Co-Author, American Bar Associa on, July 2020) “Federal Government Agrees to Global $260M Se lement with Florida Hospital Chain” (October 10, 2018) “OIG: Telehealth Equipment Dona on Presents Low Risk of Fraud and Abuse” (September 19, 2018) “OIG Report Highlights Telehealth Reimbursement Challenges” (May 10, 2018) “OIG Report Reminds PT Service Providers to Review Billing Prac ces” (April 16, 2018) “Government Dismissal under the False Claims Act: Policy Change or Much Ado About Nothing?,” Westlaw Journal White Collar Crime (March 16, 2018) “Exploring Limits Of An -Kickback Law Employee Safe Harbor” (March 5, 2018) “2018 Bipar san Budget Act and Stark Law Amendments” (February 21, 2018) “Deadline Fast-Approaching for Medicaid Managed Care Par cipa ng Providers” (November 7, 2017) “OIG Audit Discovers $51.6 M in Overpayments to Acute-Care Hospitals” (October 17, 2017) “Hidden Risks In Prac ce Acquisi ons And Joint Ventures” (May 25, 2017) “OIG Releases Compliance Program Update” (April 18, 2017) “OIG Rejects Laboratory’s Offer to Provide Free Labeling to Dialysis Facili es” (March 10, 2017) “OIG Adds New Safe Harbor Protec ons in 2017” (January 24, 2017) “Five Essen al Ques ons To Mi gate Corporate Compliance Risk” (November 18, 2016) “Safe Harbor, Safe Passage Under the An -Kickback Statute” (November 11, 2016) “False Claims Viola ons in a Post-Escobar World,” Corporate Compliance Insights (August 22, 2016) “Health Care Compliance: Tips For A Corporate Body Self-Exam” (July 14, 2016) | “Prosecutorial Discre on,” Nutri on Business Journal in Nutri on Business Journal (March 7, 2016) “Hospital ‘Medical Necessity’ Se lements: An Abuse of the False Claims Act?” (November 23, 2015) “The Park Doctrine and the Perils of “Off-Label” Promo on” (September 30, 2015 ) “DOJ Policy Memo Urges Prosecutors to Hold Individuals Accountable for Corporate Misdeeds” (September 17, 2015) “Poten al Changes to the Stark Excep ons in New CMS Proposed Rule” (July 31, 2015) “New Payment Models Bring New Healthcare Data Measurement Requirements” (June 30, 2015) “Measuring Compliance Risk in Health Care Transac ons” (February 10, 2014) “Fool’s Gold: How To Avoid Suspect Business Arrangements in Diagnos c Tes ng Ventures (November 30, 2013) “All That Gli ers Is Not Gold: The Importance of Compliance Due Diligence In Assessing Healthcare Transac on Value” (September 30, 2013) “What does the Second Circuit’s Recent Decision in United States v. Caronia Not Say,” FDLI Food and Drug Policy Forum (February 13, 2013) “Due Diligence On Execs, Board Vital When Sizing Up Companies,” Fund Director Intelligence (December 20, 2012) “Risky business: Rx drugs obtained in the secondary market,” Drug Topics – Special Report (October
2012) “Comba ng Online Counterfei ng with Help from the Lanham Act,” Italy-America Chamber of Commerce, Inc. (December 2011) “Ensuring Product Integrity and Trust in Your Supply Chain,” Chief Execu ve.net (October 5, 2011) “Billing for drug overfill: New compliance risk or old prohibi on?,” HCCA Compliance Today(October 2011) “When The Government Knows Too Much For Its Own Good,” Law360 (September 9, 2011). “Health Care Compliance on a Shoestring,” HCCA Compliance Today. “Corporate Piracy Efforts: Cost Center or Profit Center?,” Law 360. “Reforming the Major Credit Ra ng Agencies: What Hath the SEC Wrought?,” The Metropolitan Corporate Counsel. “Overfill: A Drug Sample in Sheep’s Clothing?,” BNA Pharmaceu cal Law & Industry Report. “The ‘Tone at the Top’: Can it Mi gate C-Suite Personal Liability?,” Food and Drug Law Journal. “Healthcare – Lessons From The U.S.,” Fraud Intelligence. “My Brother’s Keeper: The Rise of Independent Monitors,” The Early Warning System Report. Federal Government Agrees to Global $260M Se lement with Florida Hospital Chain (October 10, 2018) OIG: Telehealth Equipment Dona on Presents Low Risk of Fraud and Abuse (September 19, 2018) OIG Report Highlights Telehealth Reimbursement Challenges (May 10, 2018) OIG Report Reminds PT Service Providers to Review Billing Prac ces (April 16, 2018) Government Dismissal under the False Claims Act: Policy Change or Much Ado About Nothing?, Westlaw Journal White Collar Crime (March 16, 2018) Exploring Limits Of An -Kickback Law Employee Safe Harbor (March 5, 2018) 2018 Bipar san Budget Act and Stark Law Amendments (February 21, 2018) Deadline Fast-Approaching for Medicaid Managed Care Par cipa ng Providers (November 7, 2017) OIG Audit Discovers $51.6 M in Overpayments to Acute-Care Hospitals (October 17, 2017) Hidden Risks In Prac ce Acquisi ons And Joint Ventures (May 25, 2017) OIG Releases Compliance Program Update (April 18, 2017) OIG Rejects Laboratory’s Offer to Provide Free Labeling to Dialysis Facili es (March 10, 2017) OIG Adds New Safe Harbor Protec ons in 2017 (January 24, 2017) Five Essen al Ques ons To Mi gate Corporate Compliance Risk (November 18, 2016) Safe Harbor, Safe Passage Under the An -Kickback Statute (November 11, 2016) False Claims Viola ons in a Post-Escobar World, Corporate Compliance Insights (August 22, 2016) Health Care Compliance: Tips For A Corporate Body Self-Exam (July 14, 2016) Prosecutorial Discre on, Nutri on Business Journal in Nutri on Business Journal (March 7, 2016) Hospital “Medical Necessity” Se lements: An Abuse of the False Claims Act? (November 23, 2015) The Park Doctrine and the Perils of “Off-Label” Promo on (September 30, 2015 ) DOJ Policy Memo Urges Prosecutors to Hold Individuals Accountable for Corporate
Misdeeds (September 17, 2015) Poten al Changes to the Stark Excep ons in New CMS Proposed Rule (July 31, 2015) Health Services Alert (July 24, 2015) New Payment Models Bring New Healthcare Data Measurement Requirements (June 30, 2015) Measuring Compliance Risk in Health Care Transac ons (February 10, 2014) Fool’s Gold: How To Avoid Suspect Business Arrangements in Diagnos c Tes ng Ventures (November 30, 2013) All That Gli ers Is Not Gold: The Importance of Compliance Due Diligence In Assessing Healthcare Transac on Value (September 30, 2013)
Speaking Engagements Panelist at PLI Life Sciences Program, Enforcement Trends (September 13, 2019) Business Owners Seminar Series (August 9, 2019) 5th Annual Compliance Boot Camp (April 29, 2019) Hun ngton Rotary Club, “The Legal Pi alls of Running a Cash Business” (February 27, 2019) Panelist at PLI Life Sciences Program, Enforcement Trends (August 30, 2018) Panelist, “Defending an FCA Allega on: Forewarned Is Forearmed” (April 12, 2018) Panelist, FCA Defense Seminar (April 5, 2018) Panelist, “Defending a False Claims Act Allega on” (October 24, 2017) Panelist at PLI Life Sciences Program, Enforcement Trends (August 17, 2017) Panelist, NYSBA Medical Marijuana CLE Program (October 14, 2016) Panelist, American Conference Ins tute’s 4th Annual Legal, Regulatory and Compliance Forum on Dietary Supplements (June 27, 2016) Panelist, “Nursing Home Compliance Updates: HIPAA and Corporate Responsibili e,” Greater New York Healthcare Facili es Associa on (November 11, 2015) Co-Presenter, “Legal Update and Quality Management,” Greater New York Healthcare Facili es Associa on (November 19, 2014) “Risky Business: How Purchasing, Prescribing and Billing for Discounted Pharmaceu cals and Medical Devices Can Result in Criminal Prosecu on,” Dean’s Hour, Nassau Academy of Law, Nassau County Bar Associa on (January 16, 2013) “The False Claims Act and Health Care Enforcement Ac ons,” Nassau County Bar Associa on, Hospital and Health Commi ee (December 6, 2012) “Canal Street To Main Street: The Enforcement Challenges Posed By Product Counterfei ng,” The Bar Associa on of Lehigh County Bench Bar Conference, Allentown, PA (December 3, 2011) “Protec ng Your Brand/Food Safety Risks,” The Dairy Prac ces Council’s 42nd Annual Conference, Manchester, NH (November 3, 2011)“Knock-Offs, the Growing Risk of Fraudulently Manufactured Products Making Their Way Into Your Construc on Projects,” AGC 2011 Conference on Surety Bonding and Construc on Risk Management (February 2011) “Breakfast Roundtable Discussions: Tac cal Considera ons For Brand Owners In Comba ng Pi
”A
C
f i
dB
dP
W
C
(J
2011)
Piracy,” An -Counterfei ng and Brand Protec on West Coast (January 2011) “Support Services for Brand Protec on Programs,” Brand Protec on Perspec ves and Strategies Conference (October 2010) “Transforming Your An -Piracy Program From A Cost Center Into A Profit Center,” Legal IQ’s 5th Annual An -Counterfei ng & Brand Protec on Conference (September 2010) “Trends in CIAs,” 13th Annual Health Care Compliance Forum (October 2009) “Inves ga ng and Resolving Device Misbranding Cases,” American Health Lawyers Associa on, Life Sciences Law Ins tute (October 2009) “Key Compliance Issues Facing Directors and Trustees of Health Care and Life Sciences Companies,” Na onal Webcast (September 2009) “Key Compliance Issues Facing Directors and Trustees of Health Care and Life Sciences Companies,” Directors Roundtable (April 2009) “Medical Device Misbranding and Concealment of Quality Defects,” Na onal Health Care An Fraud Associa on (April 2009) “The Prosecu on of Insurance Fraud Cases in the United States A orney’s Office,” Guest Speaker, Na onal Insurance Crime Bureau (March 2009) “Claims Data: How to Get What You Want and Understand What You Got,” Department of Jus ce Seminar on Successful Strategies for Naviga ng Health Care Fraud Cases (January 2009) “Healthcare From A Corporate Counsel’s Perspec ve,” Legal Tech Conference (January 2009) “Emerging (Regulatory and Prosecutorial) Focus on Physicians,” 9th Annual Pharmaceu cal Regulatory and Compliance Congress and Best Prac ces Forum (October 2008) “Challenges Faced By In-House Counsel in the Pharmaceu cal & Healthcare Industry,” Masters Conference (October 2008) “Li ga ng Healthcare Case,” 12th Annual Healthcare Compliance Forum (October 2008) “Demys fying AML and OFAC Compliance Breakfast Briefing” (June 2008) “Ethical Perils and Challenges of E-discovery,” Federal Bar Associa on, Criminal Law Conference (June 2008) “Health Care Law Enforcement Compliance Trends and Issues,” New York City Bar Associa on (May 2008) “Federal Pricing Enforcement Update,” American Conference Ins tute Drug Pricing Conference (March 2008) “Health Care Law Enforcement Ini a ves,” Greater New York Hospital Associa on (November 2007) “Federal Pricing Enforcement Update,” 5th Annual In-House Counsel Forum on Government Regula on of Prescrip on Drug Pricing (March 2007) “Government Inves ga ons Into Allega ons of Off-Label Marke ng,” American Bar Associa on, Sec on of Li ga on, Products Liability Commi ee, 2006 Pharmaceu cal Regional CLE Workshop: Current Issues in Pharmaceu cal Li ga on and Policy (November 2006) “When Your Client’s Health Law Problems Become Your Own: Meet The AUSAs,” New York State Bar Associa on, Health Law Sec on (September 2005)
Press Interview for Healthcare Risk Management Magazine ar cle, “Coding Issues Carry Major Liability, Compliance Risks,” (July 3, 2018) Comments on Supreme Court Decision in Universal Health Services v. Escobar for FierceHealthcare (June 23, 2016) Comments on Supreme Court Decision in Universal Health Services v. Escobar for FierceHealthcare (June 23, 2016) Comments on Supreme Court Decision in Universal Health Services v. Escobar for Boston Globe (June 17, 2016) Comments on Supreme Court Decision in Universal Health Services v. Escobar for Bloomberg BNA (June 21, 2016) Comments for Natural Products Insider regarding USPlabs Indictment (November 30, 2015) Comments for Nutraingredients on USPlabs Indictment (November 19, 2015) “Ul mate Impact of Caronia Decision Uncertain, but FDA and Prosecutors Might Be More Careful,”Philly.com (December 28, 2012) “Anderson Kill Nabs Brand Expert For Co-Chair Post,” Law360 (March 18, 2011) Bar Admissions New York, United States District Court for the Southern District of New York, United States District Court for the Eastern District of New York Educa on New York University School of Law, 1987, J.D. University of Virginia, with honors, Phi Beta Kappa, 1984, B.A. Kaiser Law Firm, PLLC is a bou que law firm with offices located in 926 RXR Plaza Uniondale, NY 11556 U.S.A. We offer top-flight Whistleblower Representa on and Business Intelligence Services.
DISCLAIMER: This is an attorney advertisement. This website is designed for general information only. The information presented on this website should not be construed to be legal advice nor the formation of an attorney-client relationship. Past results do not guarantee future outcome. Attorney Advertising © 2020 Kaiser Law Firm, PLLC
Main Office: 926 RXR Plaza Uniondale, NY 11556-0926
Phone: 516-570-3071
ï¡» Phone: TOLL FREE 844-800-6657